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Unfortunately, the values for urinary ACR in the ‘Month 6
characteristics’ section of Table 1 were incorrect. They
should have read 124 (46–249) for those in the group with
serum potassium <5.0 mmol/l and 139 (51–291) for those
in the group with serum potassium ≥5.0 mmol/l.
The online version of the original article can be found at http://dx.doi.
org/10.1007/s00125-010-1922-6.
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